My research uses metabolomics-based approaches for biomarker discovery and for development of mass spectrometry-based clinical laboratory tests for metabolic disorders, which is one of goals of the Diabetes Research Center (DRC). The metabolic disorders of interest include Niemann-Pick disease type C (NPC), Krabbe disease, GM1 gangliosidosis, GM2 gangliosidosis, and Gaucher disease. I also direct the DRC Metabolomics Core and provides mass spectrometry analytical services, including quantification of targeted analytes including lipids, structural analyses and identifications, validated assay development, quantitative flux analyses, and pharmacokinetic, and pharmacodynamics analyses, untargeted metabolomics, to DRC investigators.
